Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Kai Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3062-3618; OpenAlex author ID A5100399875. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. SLC7A11-AS1 contributes to prolonged activation of activin A/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer. Co-author DOI 10.1038/s41416-025-03149-4↗
  2. Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer. First author DOI 10.3389/fonc.2022.844648↗
  3. MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protei… Co-author DOI 10.3892/ol.2022.13363↗
  4. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion via NF-κB inhibition. Co-author DOI 10.7150/thno.51976↗
  5. lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCFβ-TRCP-Mediated Degradation of NRF2 in Pancreatic Cancer. First author DOI 10.1016/j.omtn.2019.11.035↗
  6. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. First author DOI 10.1186/s12943-020-01158-w↗
  7. Author Correction: Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells. Co-author DOI 10.1038/s41419-019-1852-2↗
  8. MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protei… Co-author DOI 10.3892/ol.2018.8109↗
  9. Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells. Co-author DOI 10.1038/cddis.2017.311↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huanjie Yang · 6 shared papers, 2017–2025 · strength 0.84
  2. Qingzhu Yang · 5 shared papers, 2017–2025 · strength 0.67
  3. Huan Nie · 1 shared paper, 2025 · strength 0.27
  4. Mengmeng Li · 1 shared paper, 2025 · strength 0.27
  5. Yang-an Liu · 2 shared papers, 2018–2022 · strength 0.24
  6. Xiao Ye · 2 shared papers, 2018–2022 · strength 0.24
  7. Xinyuan Li · 1 shared paper, 2022 · strength 0.17
  8. Yuran Gao · 2 shared papers, 2017–2019 · strength 0.17
  9. Ling Zhu · 1 shared paper, 2022 · strength 0.16
  10. Xuefei Guo · 1 shared paper, 2021 · strength 0.11
  11. Yinshi Huang · 1 shared paper, 2020 · strength 0.11
  12. Xingya Guo · 1 shared paper, 2020 · strength 0.11
  13. Weiliang Jiang · 1 shared paper, 2020 · strength 0.11
  14. Rong Wan · 1 shared paper, 2020 · strength 0.11
  15. Ling‐Qiang Zhu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.